



NATH SEEDS®

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

13th August 2022

The Manager-Listing
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

The Manager-Listing
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra-Kurla Complex
Bandra (E)
Mumbai-400051

BSE Code-537291

NSE Code-NATHBIOGEN

Sub - Outcome of Board Meeting.

Ref – Regulation 30 and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements).

We inform you that the Board of Directors of the Company, at its Meeting held today i.e. on Saturday 13th August 2022, has approved the standalone unaudited financial results, for the quarter ended 30th June, 2022.

Pursuant to above-referred regulations, we enclose the following documents.

1. Statement of unaudited financial results, for the quarter ended 30th June 2022.(Annexure-I)
2. Limited Review Report of the Statutory Auditors on the aforesaid Financial Results. (Annexure-II).

The Meeting Commenced on 03:30 p.m. and Concluded on 04:30 p.m.

The above information will be made available on the Company's website www.nathbiogenes.com.

You are requested to take the above information on record.

Thanking You

Yours faithfully,
For Nath Bio-Genes (India) Limited

Devinder Khurana
Chief Financial Officer



Nath Bio-Genes (I) Ltd.

ICIN (01110M1991PL007842)

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND 3 MONTHS ENDED 30/06/2022

Rs in Lacs							
Sl. No.	Particulars	Quarter Ended			Three Months Ended		Year Ended
		30/06/2022 Unaudited	31/03/2022 Audited	30/06/2021 Unaudited	30/06/2022 Unaudited	30/06/2021 Unaudited	31/03/2022 Audited
	I Income						
	(a) Revenue from operations	20934.99	2721.18	21463.58	20934.99	21463.58	27836.23
	(b) Other Operating Income	3.98	72.58	46.71	3.98	46.71	185.47
	Total Income	20938.97	2793.76	21510.29	20938.97	21510.29	28021.70
	II Expenses						
	a) Production Expenses	4138.68	425.53	10772.45	4138.68	10772.45	11542.28
	b) Purchase of Stock-in-Trade	170.88	31.04	49.83	170.88	49.83	355.92
	c) Changes in Inventory of Produced and Traded Goods	6032.38	299.01	658.12	6032.38	658.12	498.64
	d) Employee Benefit Expense	498.38	759.92	492.59	498.38	492.59	2478.38
	e) Finance Costs	288.30	246.88	265.73	288.30	265.73	1061.10
	f) Depreciation & Amortisation Expenses	67.40	105.08	67.73	67.40	67.73	308.41
	g) Selling & Distribution Expenses	5968.65	2374.09	4010.36	5968.65	4010.36	6837.52
	h) Admin & R&D Expenditure	681.99	957.07	673.86	681.99	673.86	2399.91
	Total Expenses	17846.66	5198.63	18990.68	17846.66	18990.66	25482.16
	III Profit before Exceptional Items & Tax (I - II)	3092.31	(2404.88)	4519.63	3092.31	4519.63	2639.54
	IV Exceptional Items Income/(Expenses)	0.00	8878.19	0.00	0.00	0.00	8878.19
	V Profit Before Tax (III+IV)	3092.31	(11283.07)	4519.63	3092.31	4519.63	(6338.65)
	VI Tax Expense						
	(a) Current Tax	16.67	184.80	28.47	16.67	28.47	234.05
	(b) Earlier Year Tax	0.00	161.10	0.00	0.00	0.00	161.10
	(c) Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
	VII Net Profit for the period (V-VI)	3075.64	(11628.77)	4491.16	3075.64	4491.16	(6733.80)
	VIII Other Comprehensive Income						
	1. (a) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Income tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	2. (a) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Income tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	Total other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	0.00
	IX Total Comprehensive Income for the period (VII + VIII)	3075.64	(11628.77)	4491.16	3075.64	4491.16	(6733.80)
	X Paid Up Equity Share Capital (Face Value Rs. 10/- each)	1900.40	1900.40	1900.40	1900.40	1900.40	1900.40
	XI Reserves (excluding Revaluation Reserves) as per balance sheet of previous	55769.32	52693.68	63918.64	55769.32	63918.64	52693.68
	XII Earning per share (of Rs 10/- each) (not annualised) Basic & Diluted	16.18	(61.19)	23.63	16.18	23.63	(35.43)

NOTES:

- (1) The financial results were reviewed by the Audit Committee in meeting held on 12 August 22 and were thereafter approved by the Board of Directors at its meeting held on 13 August 2022
- (2) The company is dealing in one major product segment, i.e. Seed Cultivation
- (3) The figures have been regrouped/rearranged where ever necessary.

FOR NATH BIO-GENES (INDIA) LTD

J. N. Kaphiwal

Place : Aurangabad

Date : 13 Aug 2022

Jeevanita Kaphiwal
DIRECTOR

Regd. Office : Nath House, Nath Road, Aurangabad - 431005 (MS)
www.nathbiogenes.com



FOR GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS

Gautam
(PARTNER)

UDIN!-22032942A0YAVC3501





Gautam N Associates
Chartered Accountants

30, GNA House, Behind ABC Complex,
Mahamandir Travels Lane, Adalat Road, Aurangabad - 431 001

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY AND YEAR TO DATE UNAUDITED STANDLONE IND-AS FINANCIAL RESULTS OF THE COMPANY PURSUANT TO REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATION 2015, AS AMENDED

To
The Board of Directors,
Nath Bio-Genes (India) Limited
Aurangabad.

1. We have reviewed the accompanying statement of unaudited financial results of **Nath Bio-Genes (India) Limited** for the quarter ended 30th June 2022 and year to date results for the period 1st April 2022 to 30th June 2022 ('The Statement') being submitted by the Company pursuant to the requirements of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as modified.
2. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34- 'Interim Financial Reporting' prescribed under section 133 of the Companies Act., 2013 read with relevant rules issued there under and other recognised accounting practices and policies generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Gautam N Associates
Chartered Accountants
FRN: 103117W


Gautam Nandawat
Partner

M No: 032742

UDIN : 22032742AOYAVC3501

Place : Aurangabad

Date : 13th August 2022

